Apixaban vs. Enoxaparin after total gasterectomy in patients with gastric cancer

Efficacy and safety of apixaban versus enoxaparin as thromboprophylaxis after total gastrectomy in patients with gastric cancer: a pilot randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220530055031N6

Enrollment

Registered

2024-09-28

Start date

2024-09-22

Completion date

Unknown

Last updated

2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Intervention 1: Intervention group: They will receive oral apixaban 5-lepixa (manufactured by Actoverco) from day 2 to day 28 after surgery at a dose of 2.5 mg twice daily. The dosage will be adjusted

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients 18-year-old or older with a diagnosis of gastric cancer. Patients with gastric cancer who are candidates for total gastrectomy surgery.

Exclusion criteria

Exclusion criteria: Patients with a prior history of venous thromboembolism. Patients with a prior history of major hemorrhage.

Design outcomes

Primary

Measure	Time frame
Adherence or Compliance (Proportion of days covered). Timepoint: day 28 post-operation. Method of measurement: History and delivery of empty containers during visits.	—

Secondary

Measure	Time frame
Patients' satisfaction and quality of life. Timepoint: day 12, 28, and 60 post operation. Method of measurement: SF-8 score questionnaire.;The incidence of major bleeding. Timepoint: day 12, 28, and 60 post operation. Method of measurement: It is measured according to the definition in clinical evaluations.;The incidence of venous thromboembolism. Timepoint: day 12, 28, and 60 post operation. Method of measurement: clinical examination with Doppler ultrasound, clinical examination with CT scan.	—

Measure

Time frame

Patients' satisfaction and quality of life. Timepoint: day 12, 28, and 60 post operation. Method of measurement: SF-8 score questionnaire.;The incidence of major bleeding. Timepoint: day 12, 28, and 60 post operation. Method of measurement: It is measured according to the definition in clinical evaluations.;The incidence of venous thromboembolism. Timepoint: day 12, 28, and 60 post operation. Method of measurement: clinical examination with Doppler ultrasound, clinical examination with CT scan.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Amir Miratashi Yazdi

Tehran University of Medical Sciences

amiratashi@tums.ac.ir+98 21 6634 8500

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026